GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Shares Outstanding (Basic Average)

Tourmaline Bio (Tourmaline Bio) Shares Outstanding (Basic Average) : 24.08 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Tourmaline Bio's average basic shares outstanding for the quarter that ended in Mar. 2024 was 24.08 Mil.


Tourmaline Bio Shares Outstanding (Basic Average) Historical Data

The historical data trend for Tourmaline Bio's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Shares Outstanding (Basic Average) Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
- 20.34 4.75

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only 20.34 20.34 20.34 20.34 24.08

Tourmaline Bio Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Tourmaline Bio  (NAS:TRML) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Tourmaline Bio Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tourmaline Bio (Tourmaline Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.